We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy
Urantide acts as selective and competitive urotensin-II (UT) receptor antagonist (pKB = 8.3), which blocks hU-II induced contractions in thoracic aorta ex vivo, and has no effect on noradrenaline or endothelin 1-induced contraction or on acetylcholine-induced relaxation. It behaves as a partial agonist in a calcium mobilization assay (in CHO cells expressing hUT receptors).
CAT No:R1053
CAS No:669089-53-6
Synonyms/Alias:1: PN: WO2005023845 SEQID: 1 Claimed Protein; L-α-Aspartyl-3-mercapto-L-valyl-L-phenylalanyl-D-tryptophyl-L-ornithyl-L-tyrosyl-L-cysteinyl-L-valine Cyclic (2→7)-Disulfide;
Quick InquiryCustom Peptide SynthesisPeptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C51H66N10O12S2 |
M.W/Mr. | 1075.26 |
Sequence | DXFWXYCV(Modifications: X-2 = Pen, X-5 = Orn, Trp-4 = D-Trp, Disulfide bridge: 2-7) |
Labeling Target | Urotensin-II (UT) receptor |
Activity | Antagonist |
InChI | InChI=1S/C51H66N10O12S2/c1-27(2)41(50(72)73)60-48(70)39-26-74-75-51(3,4)42(61-43(65)33(53)24-40(63)64)49(71)58-37(21-28-11-6-5-7-12-28)45(67)57-38(23-30-25-54-34-14-9-8-13-32(30)34)47(69)55-35(15-10-20-52)44(66)56-36(46(68)59-39)22-29-16-18-31(62)19-17-29/h5-9,11-14,16-19,25,27,33,35-39,41-42,54,62H,10,15,20-24,26,52-53H2,1-4H3,(H,55,69)(H,56,66)(H,57,67)(H,58,71)(H,59,68)(H,60,70)(H,61,65)(H,63,64)(H,72,73)/t33-,35-,36-,37-,38+,39-,41-,42-/m0/s1 |
InChI Key | VXLUBANOZQJZFE-QVKHRKAHSA-N |
Isomeric SMILES | CC(C)[C@@H](C(=O)O)NC(=O)[C@@H]1CSSC([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)CCCN)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5)NC(=O)[C@H](CC(=O)O)N)(C)C |
References | In vivo daily administration of urantide for three days resulted in reduced blood TG, TC, HDL and LDL levels in rat aortic tissue, in addition to the downregulation of the expression of the inflammatory mediators CRP and MCP-1, thus improving the symptoms of AS. These effects were identified to be time-dependent. Urantide improves atherosclerosis by controlling Creactive protein, monocyte chemotactic protein1 and transforming growth factor-β expression in rats Urantide, a hU-II analogue, is a potent UT receptor antagonist that could block hU-II-induced contractions in the rat isolated thoracic aorta and displaces 125I-hU-II binding on UT receptor transfected CHO/K1 cells. Though our preliminary studies have shown that urantide had a protective effect against myocardial IR injury in rats and mice, the cardioprotection property needed to be confirmed by further study. The post-receptorial mechanism of urantide on myocardial IR injury is still not clear. It is currently known that protein kinase C (PKC) and phosphtidylinositol 3′-kinase – Akt (PI3K–Akt) signaling pathways are involved in protection against myocardial IR injury. The present study was therefore designed to confirm the protective effect of urantide against myocardial IR injury in rats and to investigate whether PKC and PI3K–Akt signaling pathways are involved in the protective effects of urantide. Protective effect of urantide against ischemia–reperfusion injury via protein kinase C and phosphtidylinositol 3′-kinase – Akt pathway |
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.
USA
Address: SUITE 115, 17 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-624-4882
Fax: 1-631-614-7828
Email: info@creative-peptides.com
Germany
Address: Industriepark Höchst, Gebäude G830
65929 Frankfurt am Main
Email: info@creative-peptides.com